Cytodyn Inc (CYDY)

[Blue Man]

Remdesivir does not show statistical significance yet is approved. Primary outcome "all mortality" is still not significant. It was not until doctors practiced what they know is effective to reach SOC today. And research continues to find what might help treat what Remdesivir cannot. That would include leronlimab as a possibility.

Researchers are now testing remdesivir in combination with antibodies and other medications.

Remdesivir also improved mortality rates for those receiving supplemental oxygen (4% with remdesivir versus 13% with placebo at day 29 of treatment). All-cause mortality among all patients was 11% with remdesivir and 15% with placebo at day 29, but this difference between the treatment groups was not large enough to rule out chance. The preliminary findings hadn’t shown an effect on mortality.

https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19